31
Participants
Start Date
May 15, 2024
Primary Completion Date
May 31, 2027
Study Completion Date
May 31, 2027
Nimotuzumab+ NALIRIFOX
"Drug: Nimotuzumab Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg, 600mg, 400mg on Day 1, 8, 15, respectively, 28 days as a cycle, up to 6 cycles.~Other Names: h-R3~Drug: NALIRIFOX Patients will receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle, up to 6 cycles.~Other Names: NALIRIFOX"
Peking Union Medical College Hospital, Beijing
Peking Union Medical College Hospital
OTHER